March 31st, 2019 – The results from a small, phase 1b clinical trial of a new experimental glioblastoma vaccine show the treatment was tolerated well by patients, slowed tumor recurrence, and prolonged patient survival.
These researchers treated 33 patients between September 2015 and March 2018 with newly diagnosed glioblastoma multiforme with the novel cancer vaccine (IGV-001).
The vaccine is created from the patient’s own tumor cells sampled during surgical removal of the primary brain tumor.
Researchers first take the cancer cells, treat them with an antisense oligodeoxynucleotide (AS-ODN) against IGF-R1, a receptor shown to drive tumor growth and metastasis, and load them with additional AS-ODN into diffusion chambers.
Then the dime-sized chambers and their contents are irradiated and implanted under the skin of the patient’s abdomen.
The phase 1b trial only enrolled patients who were scheduled to have surgery, prior to the start of standard-of-care adjuvant therapy.
The study’s results showed that patients who received the Imvax glioblastoma vaccine had longer progression-free survival and overall survival – two common measures of cancer treatment success – than the control group.
The researchers saw no vaccine-related adverse events.
The median prognosis, or overall survival, for patients treated with the highest dose of the vaccine, was 21.9 months, compared to 14.6 months for standard of care.
Median progression-free survival was 10.4 months for the highest dose vaccine, significantly higher than the 6.9 and 5.4 months in the published standard of care studies.